SIGA Technologies, Inc. SIGA announced today that it has been awarded a $7.7 million grant from the National Institutes of Health to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of Arenavirus origin.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in